Hikma Pharmaceuticals Plc Stock Price, News & Analysis

Hikma Pharmaceuticals PLC (OTC: HKMPY) is a multinational pharmaceutical company that focuses on making medicines accessible to patients in multiple regions. According to the company, it has been creating high-quality medicines for more than 40–45 years and is headquartered in the United Kingdom, with a local presence across North America, the Middle East and North Africa (MENA), and Europe. Hikma’s shares are listed on the London Stock Exchange (LSE: HIK) and on NASDAQ Dubai (HIK), and its American depositary receipts trade over the counter in the US under the symbol HKMPY.

Hikma describes itself as a global pharmaceutical group that provides a broad range of branded and non-branded generic medicines. The company states that it helps put better health within reach every day for millions of people by creating medicines and making them accessible to those who need them. It emphasizes using its insight and expertise to transform science into medicines that can be used in routine clinical practice.

Business focus and product areas

Across its communications, Hikma highlights several key areas of activity:

• Generic medicines – Hikma’s Generics business supplies oral, inhalation and other generic and specialty products in the North American market. The company notes that it has expertise in complex technologies such as nasal sprays, and that it is the largest supplier by volume of nasal sprays in the US, based on IQVIA data.
• Sterile injectables – Hikma reports that it is a top-three US supplier of sterile injectable medicines by volume, with more than 180 injectable products and a growing pipeline. Its Injectables business develops and markets injectable therapies used in hospitals and other acute care settings.
• Branded and specialty products – The company provides a broad range of branded and non-branded generic medicines, including products for pain management, infectious diseases, oncology and other therapeutic areas, as illustrated by launches such as COMBOGESIC IV (acetaminophen and ibuprofen injection), TYZAVAN (vancomycin injection, USP), and its role in commercializing STARJEMZA (ustekinumab-hmny) Injection in the US.
• Partnerships and licensing – Hikma describes itself as a leading licensing partner, entering agreements with other pharmaceutical and biotechnology companies to develop, manufacture or commercialize medicines. Examples include licensing and commercialization arrangements for COMBOGESIC IV, STARJEMZA, and trametinib tablets, as well as a commercial partnership for KLOXXADO naloxone nasal spray.
• Venture investing – Through Hikma Ventures, its strategic venture capital arm, the company invests in digital health and other healthcare technology businesses. Hikma Ventures has backed companies such as Activ Surgical and states that it aims to help bring innovative health technologies to patients around the world.

Geographic footprint and manufacturing

Hikma notes that it has a local presence across North America, MENA and Europe. In the United States, Hikma Pharmaceuticals USA highlights more than three decades of operations and significant investment in domestic manufacturing and R&D capabilities. The company reports that it operates pharmaceutical manufacturing and development sites in locations including Columbus and Cleveland, Ohio, and Cherry Hill and Dayton, New Jersey, and that it produces large volumes of finished doses of essential medicines for the US healthcare system.

Hikma states that it has thousands of colleagues worldwide (with figures such as 8,800–9,500 employees cited in different communications) who work across its global network to develop, manufacture and distribute medicines. The company emphasizes its role in working with regulators such as the US Food and Drug Administration (FDA), including addressing critical drug shortages and maintaining a strong quality inspection record.

Therapeutic and technology focus

From its announcements, Hikma’s activities span multiple therapeutic areas and technology platforms:

• Infectious diseases and sepsis – Launches such as TYZAVAN (vancomycin injection, USP), a ready-to-use or ready-to-infuse glycopeptide antibacterial indicated for septicemia, infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections in adults and pediatric patients (1 month and older) for whom appropriate dosing can be achieved, illustrate its focus on hospital-based anti-infective therapies.
• Pain management – COMBOGESIC IV (acetaminophen and ibuprofen injection) provides an opioid-free, intravenous option for the relief of mild to moderate pain and as an adjunct to opioid analgesics for moderate to severe pain in adults where IV administration is considered clinically necessary.
• Opioid overdose reversal – KLOXXADO (naloxone HCl) nasal spray 8 mg is indicated for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. Hikma manufactures this product and has entered an exclusive commercial partnership with Emergent BioSolutions for sales in the US and Canada.
• Oncology and biosimilars – Hikma has entered agreements covering oncology and biologic products, such as acquiring an FDA-approved ANDA for trametinib tablets (an orally administered kinase inhibitor used to treat certain cancers) and partnering with Bio-Thera Solutions to commercialize STARJEMZA (ustekinumab-hmny) Injection, a biosimilar referencing Stelara, in the United States.
• Diagnostics and precision medicine – In the MENA region, Hikma has partnered with Guardant Health to promote liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across solid cancers, supporting the adoption of next-generation sequencing diagnostics.
• Digital health and surgical technologies – Through Hikma Ventures, the company supports technologies such as Activ Surgical’s ActivSight Intelligent Light, which provides intraoperative visualization and real-time surgical insights.

Corporate positioning and credit profile

Hikma repeatedly notes that its debt is rated BBB or BBB- with stable or positive outlooks by rating agencies such as S&P and Fitch, depending on the specific communication. These investment-grade ratings support the company’s ability to invest in manufacturing, R&D and partnerships.

The company’s public descriptions emphasize a commitment to practical, customer-focused execution, stating that by “thinking creatively and acting practically” it provides medicines to healthcare professionals and the people they care for. Hikma presents itself as working to shape healthier communities and to expand access to essential and specialty medicines, both through its own development and manufacturing and through collaborations.

HKMPY stock and investor relevance

The HKMPY ticker represents Hikma’s presence in US over-the-counter trading via American depositary receipts, complementing its primary listings on LSE and NASDAQ Dubai. Investors researching HKMPY are typically looking at a global pharmaceutical manufacturer with:

• a focus on generic and branded medicines across multiple therapeutic areas,
• significant participation in sterile injectables and nasal spray technologies,
• a footprint spanning North America, MENA and Europe, and
• a strategy that includes licensing, partnerships and venture investments in health technologies.

According to the information provided, Hikma continues to expand its US manufacturing and R&D capabilities, develop and launch new medicines, and form partnerships that extend its reach in areas such as biosimilars, oncology, pain management, infectious disease and precision diagnostics.

Frequently asked questions about Hikma Pharmaceuticals (HKMPY)